Drugs / ET1402L1-CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03349255 | Oct 2017 → Jan 2019 | hepatocellular carcinoma | Aeon Therapeutics (Shanghai) Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET1402L1-CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03349255 ↗ |
| Route | Intravenous | “administered through intravenous infusion” NCT03349255 ↗ |
| Target | AFP | “The molecular target for ET1402L1-CART is alpha fetoprotein (AFP)” NCT03349255 ↗ |